Nifty Pharma

Nifty Pharma index soars 7% thus far in February; nears 52-week high

Thus far in the month of February 2026, Laurus Labs surged 13%, while Sun Pharmaceutical Industries and Torrent Pharmaceuticals soared 11% each.

Pharma stocks in demand; Torrent hits new high; Natco up 6% on huge volumes

At 01:13 PM on Tuesday; Nifty Pharma index, the top gainer among sectoral indices, was up 0.2 per cent, as compared to 1.1 per cent decline in the Nifty 50.

Nifty Pharma eyes breakout; Biocon, 2 others may rally up to 22%: Analyst

Kunal Shah of Mirae Asset ShareKhan expects breakout on the Nifty Pharma index above 23,500 levels; the analyst recommends Lupin, Biocon and Torrent Pharma as top sectoral stock bets.

Lupin, Biocon: Nifty Pharma gains 3% after US-India trade deal pact

According to Axis Securities, the reduction in reciprocal taxes is incrementally positive for Indian pharmaceutical companies, particularly those with significant exposure to the US market,

Zydus Lifesciences upgraded to 'Buy' at Systematix; check target here

Systematix said the recent US FDA approval of Zycubo, a Menkes disease treatment marketed by Sentynl Therapeutics, significantly enhances the company's growth outlook

Gland Pharma rises 5%, hits 1-month high on USFDA nod to eye-allergy drug

Gland Pharma jumped 4.80 per cent to ₹1,790.40, the highest level since December 3, 2025, on the National Stock Exchange.

Pharma index hits 52-week high; Glenmark, Lupin rally 3% in subdued market

In the past two trading days, the Nifty Pharma index has rallied 3.3 per cent, as compared to 0.41 per cent decline in the Nifty 50.

Indian pharma cos' new drug filings decline to 20-year low, Nomura says

Abbreviated new drug application filings have declined to 600 in the financial year 2025 (ending in September) versus 740 in the preceding year, Nomura said

2026 investment strategy: PSU banks, IT 'cheap'; defence stocks 'expensive'

Analysts think financials, metals, and IT sectors are trading at 'relatively' better values and may offer suitable entry points at current levels

Laurus Labs shares drop 3% despite analysts' bullish outlook; details here

Laurus Labs reported a strong Q2 FY26 performance, with consolidated net profit soaring multifold to ₹194.97 crore, compared with ₹19.78 crore in Q2 FY25

Tariff relief buzz lifts Nifty Pharma Index; Lupin, Aurobindo lead gains

Pharma stocks were rising in trade today as export concerns eased on US tariff report. Check out the top stocks that may benefit from US tariff relief

Pfizer soars 8%; Sun, Lupin gain up to 4%; here's what triggered the rally

Pfizer-US trade deal triggers rally in pharma stocks. Nifty Pharma and BSE Healthcare index jumped 1 per cent each; while Nifty 50 and BSE Sensex advanced 0.1 per cent each in Wednesday's early trade.

Nifty Pharma declines 2% after Donald Trump's 100% tariff on branded drugs

The index tracking domestic pharmaceutical stocks hit a low of 21,390 and then recouped some losses to end at 21,507

Stocks to Watch today, Sept 26: Pharma, IT, auto, Polycab, Rites, Eternal

Stocks to Watch today, September 26, 2025: From Pharma, auto to Polycab, here is a list of stocks that will be in focus

Sun Pharma slips 5% in 2 days, nears 52-wk low; why drug stock trades weak?

Thus far in August 2025, Sun Pharma has underperformed the market by falling 8 per cent, as compared to a 1 per cent decline in the BSE Sensex

SMS Pharmaceuticals shares zoom 10% on clean USFDA inspection report

SMS Pharmaceuticals shares rose 10 per cent after it received an Establishment Inspection Report with a No Action Indicated from the USFDA

Sun, Lupin, Dr Reddy's drop up to 4%; why are pharma stocks falling today?

Pharma shares crash: In the past four weeks, the Nifty Pharma index has slipped 5 per cent, as against 0.19 per cent decline in the Nifty 50.

Lupin shares advance 5% after Q1 results; should you buy in?

Lupin shares rose 5 per cent after the firm posted a 52 per cent year-on-year increase in net profit in Q1 FY26

Nifty Pharma down 1.5%: Granules, Biocon lead with over 2% fall; Here's why

Pharma stocks fell after Trump said tariffs will be imposed within a week, rising up to 250 per cent in 12-18 months

Emcure Pharma shares gain as JM Financial initiates coverage; check target

JM Financial initiated coverage on Emcure Pharma with a 'Buy' rating and a target price of ₹1,740, citing its growth prospects